Vitamin D derivative compound and preparation method thereof

By adding chiral structure and extending carbon chains in vitamin D derivatives and adopting specific synthetic methods, the problem of low selectivity of existing drug targets is solved, the selectivity and bioavailability of drugs is improved, and the Side effects, achieving more effective treatment of psoriasis.

CN119080662APending Publication Date: 2024-12-06XIAN QINKAI BIOTECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411212814.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The target selectivity of existing psoriasis treatment drugs is not high, resulting in more side effects of the drug.

Method used

Develop a vitamin D derivative compound that improves the selectivity and bioavailability of drugs by increasing chiral structure and extending carbon chains, combining selective protection, oxidation reaction, chiral reduction and Horner-Wadsworth-Emmons reaction to prepare Compounds with specific stereotypes are produced to reduce by-product generation and improve drug efficacy.

Benefits of technology

It improves the selectivity and bioavailability of drugs, reduces side effects, enhances the affinity for biological targets, and improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080662A_ABST
    Figure CN119080662A_ABST
Patent Text Reader

Abstract

The invention discloses a vitamin D derivative compound and a preparation method thereof.The vitamin D derivative compound comprises a compound shown in the general formula (I) or a stereoisomer shown in the general formula (I): # imgabs0 #, n is 1-5, a chiral structure and a carbon chain are added to the compound, the selectivity to a target spot can be effectively improved, and the side effect of a medicine is effectively reduced; in the preparation process, the final product is prepared through selective protection, oxidation reaction, chiral reduction and Horner-Wadsword-Emmons reaction, generation of a large number of isomers is avoided through reasonable reaction design, generation of by-products is reduced, purification difficulty is lowered, efficiency is improved, and the method is suitable for large-scale industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of pharmaceutical preparation development and relates to a vitamin D derivative compound and a preparation method thereof. Background Art

[0002] Calcipotriol, also known as calcipotriol, is a derivative of vitamin D. It can inhibit the excessive proliferation of skin cells (keratinocytes) and induce their differentiation, thereby correcting the abnormal proliferation and differentiation of psoriasis skin cells. At the same time, it regulates the release of cellular inflammatory factors, inhibits inflammatory infiltration and proliferation, and plays an anti-inflammatory role. Calverley first reported its synthesis in 1988. As a new anti-psoriatic drug, it has shown its function in treating psoriasis in many clinical trials. Studies have shown that calcipotriol acts by interacting with the vitamin D receptors in the cell nucleus. Vitamin D is present in cells involved in the pathogenesis of psoriasis, such as keratinocytes, skin adnexal cells, fibroblasts, monocytes, T lymphocytes, and activated B lymphocytes in the skin. 3 Receptors. Vitamin D 3 Drugs bind to receptors, adjust biological changes in cells, inhibit keratinocyte proliferation, enhance their morphological and biochemical differentiation, and make cells grow and reproduce according to normal rules. At the same time, experimental studies have shown that vitamin D 3 This class of drugs can interact with and regulate the cell kinin pathway in skin inflammation and immune response. Calcipotriol has a similar affinity to calcitriol for vitamin D receptors, but its effect on calcium metabolism is less than 1% of calcitriol. It can be taken for a long time with few side effects. At the same time, calcipotriol can regulate the release of cellular inflammatory factors, inhibit inflammatory infiltration and proliferation, play an anti-inflammatory role, and exert a therapeutic effect by inhibiting T lymphocyte function and neutrophil aggregation. Calcipotriol is currently one of the most effective non-glucocorticoid topical drugs for the treatment of localized psoriasis.

[0003] However, clinical efficacy shows that even with a full course of calcipotriol treatment, the clinical efficacy is 95.2%; the treatment group combined with UVB irradiation on the basis of the control group, the clinical efficacy is 80.9%, and there is a significant difference between the two groups before and after treatment, indicating that the topical calcipotriol ointment for the treatment of psoriasis has a fast onset of action, but in order to achieve the target course of treatment, adding light irradiation after use can increase the efficacy. (Wang Wenbin, Zhang Fan, He Xiang, et al., Progress in the Synthesis of Calcipotriol, Chemical Research and Application, 2016, 28(6):764-769); At present, the targets of the drugs under development for the treatment of psoriasis are mainly TNF-α (tumor necrosis factor α), interleukin and its receptor, JAK (Janus kinase) and PDE4 (phosphodiesterase 4), etc. Some target inhibitors that have been marketed or under research still have problems such as insufficient target selectivity, resulting in more drug side effects, so inhibitors targeting these existing targets still have great development prospects. Summary of the invention

[0004] In view of the problems existing in the prior art, the present invention provides a vitamin D derivative compound and a preparation method thereof, thereby solving the technical problem that the target inhibitors in the prior art have low target selectivity, resulting in more drug side effects.

[0005] The present invention is achieved through the following technical solutions:

[0006] A vitamin D derivative compound, comprising a compound represented by general formula (I), or a stereoisomer of general formula (I):

[0007] Wherein n is 1 to 5.

[0008] Preferably, the method comprises the following steps:

[0009] Step 1, reacting compound 1 with a hydroxyl protecting agent under the action of a base to obtain compound 2;

[0010] The compound 1 is Compound 2 is

[0011]

[0012] Step 2, reacting the compound 2 with 4-methylbenzenesulfonate pyridine at room temperature to obtain compound 3;

[0013] The compound 3 is

[0014] Step 3, reacting the compound 3 with an oxidant to obtain a compound 4;

[0015] The compound 4 is

[0016] Step 4, subjecting the compound 4 to a Wittig reaction with the compound 5 to obtain the compound 6;

[0017] The compound 6 is

[0018] Step 5, reacting the compound 6 with a chiral ligand and a reducing agent to obtain a compound 7 or a stereoisomer thereof;

[0019] The compound 7 is

[0020] Step 6, removing the protecting group on the compound 7 or its stereoisomer to obtain the compound 8 or its stereoisomer; the compound 8 is

[0021] Step 7, reacting the compound 8 or its stereoisomer with a hydroxyl protecting agent to obtain a compound 9 or its stereoisomer;

[0022] The compound 9 is

[0023] Step 8, the compound 9 or its stereoisomer reacts with an oxidant to obtain a compound of formula 10 or its stereoisomer; the compound 10 is

[0024] Step 9, subjecting the compound 10 or its stereoisomer to a Horner-Wadsworth-Emmons reaction with the compound 11 in an organic solvent to obtain a compound 12 or its stereoisomer;

[0025] The compound 12 is

[0026] Step 10, reacting the compound 12 or its stereoisomer with an acid to remove the protecting group, thereby obtaining the compound represented by the general formula (I) or its stereoisomer.

[0027] Preferably, the hydroxyl protecting agent used in step 1 and step 7 is any one of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, diphenylmethylsilyl and triethylsilyl.

[0028] Preferably, in step 1, the molar ratio of the compound 1 to the hydroxyl protecting agent is 1:(2-4).

[0029] Preferably, in step 2, the molar ratio of compound 2 to 4-methylbenzenesulfonate pyridine is 1:(2-4).

[0030] Preferably, in step 3, the molar ratio of the compound 3 to the oxidant is 1:(1.5-4).

[0031] Preferably, in step 4, the molar ratio of compound 4 to compound 5 is 1:(1.5-4.5), the reaction temperature is 25-80° C., and the reaction time is 4-12 h.

[0032] Preferably, in step 5, the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:(0.6-1.5):(1.0-3.5).

[0033] Preferably, the oxidizing agent used in step 3 and step 8 is any one of Dess-Martin periodinane, pyridinium chlorochromate and pyridinium dichromate.

[0034] Preferably, in step 10, the acid is any one or more of DL-camphorsulfonic acid, L-camphorsulfonic acid, and D-camphorsulfonic acid; in step 10, the molar ratio of the compound 12 to the acid is 1:(2-5.5).

[0035] Compared with the prior art, the present invention has the following beneficial technical effects:

[0036] The present invention discloses a vitamin D derivative compound. First, the compound has a chiral structure. In vivo, many important biological macromolecules (such as proteins, DNA and RNA) have chiral characteristics and usually only interact with small molecules (such as drugs) of specific chirality. Therefore, chiral drug molecules can act on biological targets more accurately, reduce nonspecific binding with non-targets, thereby improving drug efficacy and reducing side effects. In addition, the structure of the present invention also increases the carbon chain structure. The extension of the carbon chain can change the lipid solubility and bioavailability of the molecule, and effectively promote the absorption, distribution, metabolism and excretion process of the drug in the body. In addition, the extension of the carbon chain also provides more binding sites and spatial conformations for the molecule, so that it can be more closely bound to the biological target, effectively improving the selectivity, and effectively reducing the side effects of the drug.

[0037] In addition, the present invention also discloses a method for preparing the above-mentioned vitamin D derivative compounds. Through the selective protecting group, it is ensured that in the subsequent reaction, only the target functional group participates in the reaction, while other non-target functional groups remain as they are. Then, the product of step 1 is selectively removed from the protecting group with 4-methylbenzenesulfonic acid pyridine to obtain compound 3. Then, compound 3 is reacted with an oxidant for oxidation reaction to change the functional group of the molecule and increase its polarity. Then, it is subjected to Wittig reaction with compound 5, and then an important reducing agent reaction is carried out. This process realizes the chirality control of specific carbon atoms, thereby obtaining a product with a specific stereo configuration, which is crucial for improving the selectivity of the drug and reducing side effects. Then, the hydroxyl group of the six-membered carbon ring is deprotected, the upper protecting group of the chiral carbon, the hydroxyl group of the six-membered carbon ring is oxidized, and the Horner-Wadsworth-Emmons reaction is carried out to effectively extend the carbon chain, introduce specific functional groups, and finally obtain the target product by deprotecting the chiral carbon. That is, in the present invention, the final product is obtained through selective protection, oxidation reaction, chiral reduction, and Horner-Wadsworth-Emmons reaction. The reasonable reaction design avoids the generation of a large number of isomers, reduces the generation of by-products, reduces the difficulty of purification, and improves the efficiency.

[0038] Further, the hydroxyl protecting agents used in the steps 1 and 7 are any one of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, diphenylmethylsilyl and triethylsilyl. First, these silicon-based protecting groups show good stability under a variety of reaction conditions, including stability to acids, bases, oxidants and reducing agents, and this stability ensures that the hydroxyl group can safely participate in subsequent reactions under a protected state without unexpected side reactions. Secondly, these silicon-based protecting groups can usually be combined with hydroxyl groups through simple chemical reactions to form stable silicon ether or silicon ester structures, and these reaction conditions are mild, easy to control, and have a high yield. After synthesizing the target product, these silicon-based protecting groups can be removed by methods with mild reaction conditions such as hydrolysis and fluorination to regenerate the original protected hydroxyl group. This easy deprotection property makes the entire synthesis process more flexible and efficient. It cannot be trimethylsilyl, because the trimethylsilyl protection is easily hydrolyzed and the protecting group easily falls off.

[0039] Further, in step 1, the molar ratio of the compound 1 to the hydroxyl protecting agent is 1: (2-4). First, appropriately increasing the amount of the hydroxyl protecting agent can ensure that the hydroxyl group in the compound 1 is fully protected. Since there are some side reactions or incomplete reactions during the reaction, increasing the amount of the protecting agent can increase the conversion rate of the reaction, so that more compound 1 is converted into the desired protected product. In addition, when the hydroxyl protecting agent is excessive, the interference of the unreacted compound 1 in the subsequent steps can be more effectively reduced. The unreacted hydroxyl group will affect the selectivity and efficiency of the subsequent reaction and may even lead to the formation of by-products. Therefore, by increasing the amount of the protecting agent, the residual amount of the unreacted product can be reduced, and the reliability and purity of the subsequent steps can be improved. At the same time, fully protecting the hydroxyl group can make the product have higher purity and stability, because the protecting group can stabilize the hydroxyl group and prevent it from unnecessary reaction or degradation in the subsequent steps. Therefore, by optimizing the amount of the hydroxyl protecting agent, a higher quality protected product can be obtained, providing a better raw material basis for the subsequent steps.

[0040] Further, in step 2, the molar ratio of compound 2 to 4-methylbenzenesulfonate pyridine is 1: (2-4). First, the reaction of compound 2 with 4-methylbenzenesulfonate pyridine can remove the protecting group at a specific position in compound 2. Properly increasing the amount of 4-methylbenzenesulfonate pyridine can ensure that the protecting group in compound 2 is removed more effectively. In the deprotection reaction, if the deprotection agent is insufficient, some protecting groups may not be completely removed, or other unnecessary side reactions may be triggered. Increasing the amount of 4-methylbenzenesulfonate pyridine can inhibit the occurrence of these side reactions and improve the selectivity of the deprotection reaction and the purity of the product. Adequate deprotection reaction can ensure that a high yield and high purity deprotection product is obtained, which is crucial for the smooth progress of subsequent steps and the quality of the final product. By optimizing the amount of 4-methylbenzenesulfonate pyridine, the yield and purity of the product can be maximized.

[0041] Further, in step 3, the molar ratio of the compound 3 to the oxidant is 1: (1.5-4). Properly increasing the amount of the oxidant can ensure that the target functional group in the compound 3 is fully oxidized. Increasing the amount of the oxidant can increase the reaction rate and conversion rate, so that more compound 3 is converted into the desired oxidation product, which helps to reduce the interference of unreacted compound 3 in subsequent steps, improve the efficiency of the overall reaction and the purity of the product. If the oxidant is insufficient, it may cause some compounds 3 to fail to be completely oxidized, or induce other unnecessary side reactions to generate by-products, and increasing the amount of the oxidant can inhibit the occurrence of these side reactions and improve the purity and yield of the product. At the same time, by adjusting the amount of the oxidant, the structure and properties of the oxidation product can be controlled within a certain range to meet the requirements of subsequent steps or the final product.

[0042] Further, in step 4, the molar ratio of compound 4 to compound 5 is 1:(1.5-4.5), which can make the Wittig reaction temperature 25-80°C, the reaction time 4-12h, and the appropriate molar ratio can ensure efficient collision and reaction between reactants. Within this range, the molar ratio of compound 4 to compound 5 allows sufficient reactant contact, thereby accelerating the reaction rate and improving the efficiency of product generation. In addition, the reaction conditions allow the reaction to be carried out at a lower temperature, reducing the side reactions and product degradation caused by high temperature. At the same time, the longer reaction time ensures that the reaction is fully carried out. By accurately controlling the molar ratio of the reactants and the reaction conditions, the generation of by-products can be minimized, and the selectivity and purity of the target product can be improved, which helps the smooth progress of subsequent steps and the quality control of the final product.

[0043] Further, in step 5, the molar ratio of compound 6 to chiral ligand and reducing agent is 1:(0.6-1.5):(1.0-3.5). The addition of chiral ligand is the key to realize asymmetric reduction reaction. By accurately controlling the molar ratio of chiral ligand to compound 6, the concentration of chiral ligand in the reaction system can be optimized, thereby improving the asymmetric selectivity of the reaction. Higher asymmetric selectivity means that the proportion of target chiral isomer in the product is higher. The amount of reducing agent is crucial to the reaction rate and conversion rate. Within the molar ratio range, the amount of reducing agent is sufficient to ensure the effective reduction of compound 6 while avoiding the side reactions that may be caused by excessive reducing agent. The appropriate amount of reducing agent can improve the reaction efficiency and shorten the reaction time. By optimizing the amount of chiral ligand and reducing agent, the generation of by-products can be reduced, the purity and yield of the target product can be improved, and the high-purity product is conducive to the smooth progress of subsequent steps and the quality control of the final product.

[0044] Further, the oxidant used in the step 3 and step 8 is any one of Dess-Martin periodinane, pyridinium chlorochromate and pyridinium dichromate. First, these three oxidants are strong oxidants, which can effectively oxidize functional groups such as alcohols and aldehydes to corresponding products such as ketones and carboxylic acids. They have a high degree of reactivity and selectivity, and can complete oxidation reactions under mild conditions to improve reaction efficiency. In addition, compared to other oxidants, such as potassium permanganate or chromic anhydride, Dess-Martin periodinane, PCC and PDC usually do not require extreme reaction conditions during the reaction, such as high temperature or strong acid environment, which makes them more suitable for temperature-sensitive substrates or reaction systems that need to maintain product structure. At the same time, these three oxidants usually show good chemical selectivity during the oxidation process, can be oxidized for specific functional groups, without affecting other functional groups, and this selectivity helps to reduce the generation of by-products and improve the purity and yield of the product. In addition, Dess-Martin periodinane, PCC and PDC can usually be removed by simple post-treatment steps after the reaction is completed, such as extraction, washing, etc., and their by-products are relatively easy to handle and will not cause too much trouble to the subsequent steps.

[0045] Further, in step 10, the acid is any one or more of DL-camphorsulfonic acid, left-handed camphorsulfonic acid, and right-handed camphorsulfonic acid. First, camphorsulfonic acid and its derivatives (such as left-handed and right-handed camphorsulfonic acid) are commonly used chiral resolution reagents. They can form diastereoisomer salts with chiral compounds. These salts have different solubility or crystallization properties in solvents, so that chiral resolution can be achieved by methods such as crystallization and filtration, which is very important for preparing high-purity chiral compounds. Using camphorsulfonic acid for chiral resolution can significantly improve the chiral purity of the product.

[0046] Further, in step 10, the molar ratio of compound 12 to acid is 1:(2-5.5). First, a higher amount of acid helps to ensure that the protecting group is completely removed. The presence of the protecting group will interfere with subsequent reactions or affect the properties of the final product. Therefore, complete deprotection is the key to obtaining high-quality compounds of general formula (I). An appropriate molar ratio can accelerate the reaction rate and shorten the reaction time. Within this range, the reaction between the acid and compound 12 can be carried out efficiently, thereby improving the efficiency of the overall reaction. A higher amount of acid helps to reduce the generation of impurities without removing the protecting group, thereby improving the purity of the product. The improvement of purity is crucial for the smooth progress of subsequent steps and the application of the final product. BRIEF DESCRIPTION OF THE DRAWINGS

[0047] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.

[0048] Figure 1 The synthetic flow chart of a vitamin D derivative compound in Example 1 of the present invention.

[0049] Figure 2 This is a synthetic flow chart of a vitamin D derivative compound in Example 2 of the present invention; DETAILED DESCRIPTION

[0050] In order to enable those skilled in the art to understand the characteristics and effects of the present invention, the following is a general description and definition of the terms and expressions mentioned in the specification and claims. Unless otherwise specified, all technical and scientific terms used in the text are the common meanings understood by those skilled in the art for the present invention. In the event of a conflict, the definition in this specification shall prevail.

[0051] The theories or mechanisms described and disclosed herein, whether correct or incorrect, should not limit the scope of the present invention in any way, that is, the present invention can be implemented without being limited by any specific theory or mechanism.

[0052] Herein, all features such as values, quantities, contents and concentrations defined in the form of numerical ranges or percentage ranges are for simplicity and convenience only. Accordingly, the description of numerical ranges or percentage ranges should be considered to have included and specifically disclosed all possible secondary ranges and individual values ​​within the range (including integers and fractions).

[0053] In this document, unless otherwise specified, “includes,” “including,” “contains,” “has,” or similar terms cover the meanings of “consisting of” and “mainly consisting of,” for example, “A includes a” covers the meanings of “A includes a and other” and “A only includes a.”

[0054] In this document, in order to make the description concise, not all possible combinations of various technical features in various embodiments or examples are described. Therefore, as long as there is no contradiction in the combination of these technical features, the various technical features in various embodiments or examples can be combined arbitrarily, and all possible combinations should be considered to be within the scope of this specification.

[0055] The present invention provides a vitamin D derivative compound, characterized in that it comprises a compound represented by general formula (I), or a stereoisomer of the compound represented by general formula (I):

[0056] Wherein n is 1 to 5.

[0057] In a preferred embodiment, the general formula (I) is formula (II):

[0058]

[0059] The compound of formula (II) is named as (1R, 2R, 3R, Z)-5-(2-((1R, 3aS, 7aR, E)-1-((2R, 5S, E)-5-cyclopropyl-5-hydroxypent-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-2-(3-hydroxypropoxy)-4-methylenecyclohexane-1,3-diol and has a molecular formula of C 30 H 46 O 5 , molecular weight 486.7, this compound has broad application prospects in the treatment of psoriasis.

[0060] In a more preferred embodiment, the general formula (I) is formula (III):

[0061]

[0062] At the same time, if Figure 1 The present invention also discloses a method for preparing the compound represented by the above general formula (I), comprising the following steps:

[0063] The preparation method uses compound 1 as a raw material, and obtains compound 2 through hydroxyl protection in step 1; compound 2 is selectively deprotected through hydroxyl in step 2 to obtain compound 3; compound 3 is oxidized through step 3 to obtain compound 4; compound 4 is subjected to Wittig reaction to obtain compound 6; compound 6 is reduced through step 5 to obtain compound 7 or its stereoisomer; compound 7 or its stereoisomer is deprotected through hydroxyl in step 6 to obtain compound 8 or its stereoisomer; compound 8 or its stereoisomer is selectively protected through hydroxyl in step 7 to obtain compound 9 or its stereoisomer; compound 9 or its stereoisomer is oxidized through step 8 to obtain compound 10 or its stereoisomer; compound 10 or its stereoisomer is subjected to Horner-Wadsworth-Emmons reaction to obtain compound 12 or its stereoisomer; compound 12 or its stereoisomer reacts with an acid and is deprotected through hydroxyl in step 10 to obtain the vitamin D derivative compound.

[0064] Specifically, in the above reaction process,

[0065] Step 1, using compound 1 as a starting material, reacting in an organic solvent reaction system, and protecting the hydroxyl group with a hydroxyl protecting agent under the action of a base to obtain compound 2.

[0066] In the product compound 2 obtained in the above step 1, the added hydroxyl protecting agent is any one of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, diphenylmethylsilyl and triethylsilyl. The organic solvent in step 1 is any one or more of dichloromethane, chloroform and 1,2-dichloroethane; wherein the molar ratio of compound 1 to the hydroxyl protecting agent is 1:(2-4).

[0067] Step 2, compound 2 is subjected to selective removal of the protecting group in an organic solvent reaction system to obtain compound 3.

[0068] In step 2, the organic solvent is any one or more of dichloromethane, tetrahydrofuran and 2-methyltetrahydrofuran; in step 2, compound 2 is selectively deprotected at room temperature using 4-methylbenzenesulfonate pyridine in an organic solvent reaction system to obtain compound 3. The molar ratio of compound 2 to the deprotection reagent, i.e., 4-methylbenzenesulfonate pyridine, is 1:(2-4). The selective deprotection of compound 2 using a strong acid or a weak acid in the deprotection reagent is not effective and produces a large amount of by-products. During the experiment, 4-methylbenzenesulfonate pyridine was used to obtain compound 3 with a high yield and a single product.

[0069] Step 3, adding an oxidant to the compound 3 in an organic solvent reaction system to obtain compound 4.

[0070] In step 3, the oxidant includes any one of Dess-Martin periodinane, pyridinium chlorochromate (PCC), pyridinium dichromate (PDC) and a mixture of sodium hypochlorite and TEMPO (sodium hypochlorite / TEMPO), wherein TEMPO is 2,2,6,6-tetramethylpiperidinyl oxide; in step 3, the organic solvent is any one or more of dichloromethane, tetrahydrofuran and 2-methyltetrahydrofuran; further, the molar ratio of compound 3 to the oxidant is 1:(1.5-4). In this step, compound 3 is first dissolved in an organic solvent, and then an alkaline compound is added, and then the oxidant and the additive (the additive can be potassium bromide) are mixed and dissolved uniformly and then slowly added; the alkaline compound in the reaction is NaHCO 3 、NaHPO 4 and NaH 2 PO 4 The reaction temperature of step 3 is -10 to 10°C.

[0071] Step 4, namely Wittig reaction, the compound 4 and compound 5 undergo Wittig reaction in an organic solvent to obtain compound 6.

[0072] Among them, compound 5 is

[0073] In step 4, the organic solvent is one or more of tetrahydrofuran, 2-methyltetrahydrofuran and N,N-dimethylformamide; the molar ratio of compound 4 to compound 5 is 1:(1.5-4.5), compound 4 and compound 5 are subjected to Horner-Wadsworth-Emmons reaction in an organic solvent, the reaction temperature is 25-80°C, the reaction time is 4-12h, and compound 6 is obtained; when compound 4 and compound 5 are selected, they can react directly under heating conditions, the reaction yield is high and the product is single.

[0074] Step 5, the compound 6 is subjected to chiral reduction reaction in an organic solvent system to obtain compound 7 or a stereoisomer thereof.

[0075] In step 5, the organic solvent is one or more of tetrahydrofuran, 2-methyltetrahydrofuran, methanol and ethanol; in the chiral reduction, the compound 6 reacts with the chiral ligand under the reduction of the reducing agent to obtain compound 7 or its stereoisomer; the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:(0.6-1.5):(1.0-3.5). In the chiral reduction reaction, the chiral catalyst used is any one of (R)-2-methyl-CBS-oxazaborolidine, (R)-2-isopropyl-CBS-oxazaborolidine, (S)-2-methyl-CBS-oxazaborolidine solution or (S)-2-isopropyl-CBS-oxazaborolidine. In this step, the reaction temperature is -50--10°C and the reaction time is 2-8h.

[0076] Step 6, removing the protective group of the compound 7 or its stereoisomer in an organic solvent reaction system to obtain compound 8 or its stereoisomer.

[0077] In step 6, the organic solvent is any one or more of dichloromethane, tetrahydrofuran and 2-methyltetrahydrofuran;

[0078] Step 7, the compound 8 or its stereoisomer is subjected to selective protection of the hydroxyl group in an organic solvent to obtain compound 9 or its stereoisomer.

[0079] In step 7, the obtained product compound 9 or its stereoisomers wherein R2 is one of tert-butyldimethylsilyl, triisopropylsilyl and triethylsilyl, but not trimethylsilyl. In step 7, the organic solvent is any one or more of dichloromethane, chloroform and 1,2-dichloroethane;

[0080] Step 8: Add an oxidant to the compound of formula 9 or its stereoisomer in an organic solvent to react to obtain a compound of formula 10 or its stereoisomer.

[0081] In step 8, the oxidant includes any one of Dess-Martin periodinane, pyridinium chlorochromate and pyridinium dichromate; the organic solvent in step 8 is any one or more of dichloromethane, tetrahydrofuran and 2-methyltetrahydrofuran; the molar ratio of the compound 9 or its stereoisomer to the oxidant is 1:(1.5-4.0).

[0082] Step 9, i.e., Horner-Wadsworth-Emmons reaction, the compound of formula 10 or its stereoisomer is subjected to Horner-Wadsworth-Emmons reaction with the compound of formula 11 in an organic solvent at a reaction temperature of -80°C to -30°C to obtain a compound of formula 12 or its stereoisomer.

[0083] Wherein, compound 11 is:

[0084] In step 9, the organic solvent is at least one of tetrahydrofuran and 2-methyltetrahydrofuran; the molar ratio of the compound of formula 10 or its stereoisomer to the compound of formula 11 is 1:(1.2-3.5).

[0085] Step 10, adding an acid to the compound of formula 12 or its stereoisomer in an organic solvent to remove the protecting group to obtain a compound of formula 13 or its stereoisomer, i.e., a vitamin D derivative compound.

[0086] In step 10, the acid is any one or more of DL-camphorsulfonic acid, L-camphorsulfonic acid, and D-camphorsulfonic acid; wherein DL-camphorsulfonic acid is a mixture of L-camphorsulfonic acid and D-camphorsulfonic acid. In step 10, the organic solvent is at least one of tetrahydrofuran and 2-methyltetrahydrofuran; the molar ratio of the compound of formula 12 or its stereoisomer to the acid is 1:(2-5.5).

[0087] The vitamin D derivative compounds of the present invention and the preparation method thereof, the vitamin D derivative compounds are Figure 2 The compound of formula 13 obtained in the preparation method can be used as a drug for treating psoriasis. In the preparation method, the compound of formula 1 is used as the starting material, and the compound of formula 13 is obtained through selective protection, oxidation reaction, chiral reduction, and Horner-Wadsworth-Emmons reaction. The generation of a large number of isomers is avoided through reasonable reaction design, the difficulty of purification is reduced, and the efficiency is improved; the tributyl phosphate reagent can react with the compound of formula 4 at room temperature, avoiding the by-products generated by the reaction, with low cost and high yield; the compound of formula 13 can obtain satisfactory results through crystallization, which is suitable for large-scale industrial production.

[0088] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0089] The following examples use conventional instruments and equipment in the art. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions or under conditions recommended by the manufacturer. The various raw materials used in the following examples are conventional commercial products unless otherwise specified, and their specifications are conventional specifications in the art. In the specification of the present invention and the following examples, unless otherwise specified, "%" means weight percentage, "part" means weight part, and ratio means weight ratio.

[0090] Example 1

[0091] A method for preparing a vitamin D derivative compound, such as Figure 1 As shown, the specific steps include:

[0092] S1: Preparation of intermediate 2 (compound of formula 2):

[0093] 60 g of the compound of formula 1, 500 mL of dichloromethane (DCM), and 64 g of imidazole were added under nitrogen protection, stirred evenly, cooled to -5°C, and triethylsilyl chloride DCM solution (107 g, dissolved in 10 mL of dichloromethane) was added dropwise. The system temperature was maintained at -5°C to 5°C during the addition process. The reaction was continued for 1 hour after the addition was completed. The product was analyzed by thin-layer chromatography (TLC). Chromatography, TLC) detection reaction (developing agent n-hexane: ethyl acetate = 4:1 development, phosphomolybdic acid color development, Formula 1 compound Rf ≈ 0.2, Formula 2 compound Rf ≈ 0.9), after the reaction, add 300mL of water to the system, separate the phases, extract the aqueous phase with DCM (100mL*2), wash the organic phase with 500mL×2 water, combine the organic phases and dry them with anhydrous sodium sulfate for 30min, filter, and distill under reduced pressure until no fraction flows out (-0.09~-0.06Mpa, 30.0~35.0℃) to obtain a colorless oily crude product. Purify by column chromatography, elute with petroleum ether (PE), and distill under reduced pressure until no fraction flows out (-0.09~-0.06Mpa, 30.0~35.0℃) to obtain a colorless oily compound of Formula 2 (122.7g, 98.5%).

[0094] 1H NMR (600MHz, Chloroform-d) δ4.03 (d, J=2.8Hz, 1H), 3.61 (dd, J=9.6, 3.5Hz, 1H), 3.20 (dd, J=9.7, 8.1Hz, 1H), 1.96 (dt , J=12.6, 3.3Hz, 1H), 1.86–1.70 (m, 2H), 1.69–1.64 (m, 1H), 1.60–1.55 (m, 1H), 1.52 (tdd, J=10.0, 5.5, 3.2Hz, 1H), 1.3 9–1.31 (m, 3H), 1.27 (ddd, J=10.8, 3.3, 1.8Hz, 1H), 1.20 (ddd, J=13.1, 7.1, 2.4Hz, 1H), 1.11 (td, J=13.1, 3.5Hz, 1H), 1 .04 (q, J=9.7Hz, 1H), 0.98 (d, J=6.5Hz, 3H), 0.95 (td, J=8.0, 5.0Hz, 18H), 0.91 (s, 3H), 0.57 (dq, J=19.5, 7.9Hz, 12H).

[0095] 13 C NMR (151 MHz, CDCl 3 )δ69.36, 67.60, 53.54, 52.88, 42.26, 40.69, 38.78, 34.69, 26.85, 23.17, 17.69, 16.81, 13.62, 6.95, 6.84, 4.96, 4.47.

[0096] S2: Preparation of intermediate 3 (compound of formula 3):

[0097] 124 g of the compound of formula 2 and 220 mL of tetrahydrofuran were stirred evenly, cooled to -5°C to 5°C, and a tetrahydrofuran solution of tetrabutylammonium fluoride trihydrate (62.5 g, dissolved in 400 mL of THF) was added dropwise. After the addition was completed, the reaction was allowed to proceed for 0.5-2 hours. After the reaction was detected by TLC (developing agent: n-hexane: ethyl acetate = 10:1, phosphomolybdic acid was used for color development, Rf value of the compound of formula 2 was ≈0.9, and Rf value of the compound of formula 3 was ≈0.4), water was added to quench, phases were separated, the aqueous phase was extracted with ethyl acetate (EA) (200 mL*2), the organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure until no fraction flowed out (-0.09 to -0.06 MPa, 40.0 to 45.0°C) to obtain a colorless oily crude product. The product was purified by column chromatography and distilled under reduced pressure until no fraction flowed out (-0.09 to -0.06 MPa, 40.0 to 45.0° C.) to obtain the compound of formula 3 (90.8 g, 98.9%) as a colorless oil.

[0098] 1 H NMR (600MHz, Chloroform-d) δ4.04 (d, J=2.8Hz, 1H), 3.63 (dd, J=10.5, 3.2Hz, 1H), 3.36 (dd, J=10.4, 6.8Hz, 1H), 1.95 (d, J=12.7Hz, 1H), 1.86–1.73 (m, 2H), 1.71–1.65 (m, 1H), 1.62–1.57 (m, 1H), 1.54 (ddd, J=10.1, 6.8 , 3.4Hz, 1H), 1.51–1.48 (m, 1H), 1.37 (dtd, J=14.8, 5.5, 4.5, 3.0Hz, 3H), 1.33–1.28 (m, 1H), 1.12 (ddd, J=13 .2, 10.0, 6.7Hz, 2H), 1.02 (d, J=6.6Hz, 3H), 0.96 (d, J=1.0Hz, 2H), 0.95–0.92 (m, 9H), 0.55 (q, J=8.0Hz, 6H).

[0099] 13 C NMR (151 MHz, CDCl 3 )δ69.29, 67.99, 53.14, 52.89, 42.16, 40.66, 38.31, 34.63, 26.82, 23.08, 17.67, 16.67, 13.58, 6.93, 4.95.

[0100] S3: Preparation of intermediate 4 (compound of formula 4):

[0101] Preparation of TEMPO / KBr solution: Weigh 9 g of tetramethylpiperidinium N-oxide (TEMPO) and dissolve it in 90 mL of dichloromethane, add 27 g of potassium bromide and 90 mL of water, stir to completely dissolve the potassium bromide, stir for 20 min, and set aside.

[0102] Add 92 g of the compound of formula 3 into a clean 5L three-necked flask, add 900 mL of dichloromethane and stir evenly, cool to 0-5.0°C, add 450 mL of saturated sodium bicarbonate solution dropwise into the three-necked flask, slowly add the above-prepared TEMPO / KBr solution dropwise into the reaction flask, control the reaction temperature at 0-5.0°C during the addition process, and stir for 20-25 minutes after the addition is completed. Then, a mixed solution of sodium hypochlorite (450 mL) / saturated sodium bicarbonate aqueous solution (450 mL) was added dropwise, and the system temperature was controlled at 0-5.0°C. After the addition was completed, the reaction was allowed to proceed for 0.5-1 hour. The reaction was detected by TLC (developing solvent n-hexane:ethyl acetate=10:1, Rf≈0.4 for the compound of formula 3, Rf≈0.9 for the compound of formula 4, and phosphomolybdic acid was used for color development). After the reaction was completed, the mixture was allowed to stand, phases were separated, and the mixture was extracted with dichloromethane (200 mL*2 times). The organic phases were combined, washed with 500 mL of saturated brine, dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure until no fraction flowed out (25.0-35.0°C, -0.09-0.06 MPa) to obtain a colorless liquid compound of formula 4 (85.6 g, 93.7%, HPLC purity: 95%). The specific conditions for detecting the four compounds by HPLC were as follows: chromatographic column: Agilent 5TC-C18(2)250*4.6mm, 5μm; column temperature: 30°C; flow rate: 1.0mL / min, wavelength: 197nm, mobile phase: acetonitrile:water=40:60.

[0103] 1 H NMR (600MHz, Chloroform-d) δ4.07 (d, J=2.7Hz, 1H), 2.35 (ddt, J=13.9, 7.1, 3.3Hz, 1H), 1.93–1.88(m, 1H), 1.85–1.80(m, 2H), 1.72–1.60(m, 3H), 1.44–1.41(m, 2H), 1. 40–1.37 (m, 2H), 1.26 (ddt, J=11.3, 5.1, 2.5Hz, 2H), 1.21–1.15 (m, 1H), 1.09 (d, J=6 .8Hz, 3H), 0.96 (d, J=1.2Hz, 3H), 0.94 (d, J=7.9Hz, 9H), 0.56 (dd, J=8.0, 3.7Hz, 6H).

[0104] 13 C NMR (151 MHz, CDCl 3 )δ205.37, 69.06, 52.43, 51.75, 49.17, 42.67, 40.52, 34.58, 26.21, 23.31, 17.60, 13.91, 13.34, 6.92, 4.93.

[0105] S4: Preparation of intermediate 6 (compound of formula 6):

[0106] Weigh 160g of the compound of formula 4 and 160mL of tetrahydrofuran, add them into a 500mL three-necked flask in sequence, stir, add 25.6g of cyclopropylcarbonylmethylenetributylphosphine (Wittig reagent), protect with argon, heat to 45°C for 1-2 hours, and detect the reaction by TLC (PE:EA=20:1, Rf≈0.7 for the compound of formula 4, Rf≈0.6 for the compound of formula 6, color development with phosphomolybdic acid). After the reaction is completed, distill under reduced pressure until no fraction flows out (40-45°C, -0.09-0.08Mpa), purify by column chromatography, and obtain 141.7g of light yellow oil, with a yield of 88.5%.

[0107] 1 H NMR (600MHz, Chloroform-d) δ6.75 (dd, J=15.7, 8.9Hz, 1H), 6.13 (d, J=15.8Hz, 1H), 4.03 (d, J=2.7Hz, 1H ), 2.27 (ddt, J=15.8, 9.2, 6.7Hz, 1H), 2.10 (tt, J=7.9, 4.6Hz, 1H), 1.94 (dt, J=12.4, 3.5Hz, 1H), 1.81 (t t, J=14.7, 4.6Hz, 1H), 1.71–1.63 (m, 2H), 1.57 (ddt, J=18.8, 12.1, 6.0Hz, 1H), 1.41–1.32 (m, 3H), 1.24– 1.13 (m, 4H), 1.10–1.04 (m, 5H), 0.97–0.91 (m, 12H), 0.88 (dd, J=7.7, 3.5Hz, 2H), 0.55 (q, J=7.9Hz, 6H).

[0108] 13 C NMR (151 MHz, CDCl 3 )δ200.64, 152.48, 128.06, 69.26, 55.72, 52.94, 42.50, 40.68, 39.64, 34.58, 27.40, 22.98, 19.21, 18.67, 17.66, 13.79, 10.88, 6.93, 4.93.

[0109] S5: Preparation of intermediate 7 (compound of formula 7):

[0110] Prepared 30% (R)-2-methyl-CBS-oxazole borane tetrahydrofuran / borane tetrahydrofuran solution: 10 mL of 30% (R)-2-methyl-CBS-oxazole borane solution and 30 mL of (1M) borane tetrahydrofuran were added into a 100 mL single-necked bottle, stirred and mixed for later use.

[0111] Weigh 10g of compound 6 into a three-necked flask, add 100mL of tetrahydrofuran, stir to dissolve, protect with argon, cool to -50℃~-45℃, slowly drop the above-configured 30% (R)-2-methyl-CBS-oxazolidinone tetrahydrofuran / borane tetrahydrofuran solution, react for 1~2 hours, and detect the reaction by TLC (PE:EA=8:1, compound 6 Rf≈0.9, compound 6 Rf≈0.6, phosphomolybdic acid color development). After the reaction is completed, pour the reaction solution into 100mL of ice water, stir for 10 minutes, extract with ethyl acetate, wash with saturated sodium chloride aqueous solution, dry with anhydrous sodium sulfate, and distill under reduced pressure until no fraction flows out (35~40℃, -0.09~-0.08Mpa), remove the solvent, purify by column chromatography, obtain a crude product, and prepare by HPLC low-temperature crystallization to obtain 5.56g of compound 7, with a yield of 55.2%.

[0112] 1 H NMR (600MHz, Chloroform-d) δ5.43 (t, J=6.9Hz, 2H), 4.02 (q, J=2.7Hz, 1H), 3.43 (dd, J=7.8, 5. 8Hz, 1H), 2.10–2.01 (m, 1H), 1.93 (dt, J=12.6, 3.4Hz, 1H), 1.86–1.75 (m, 1H), 1.70–1.50 (m, 4H) , 1.39–1.29(m, 3H), 1.25–1.18(m, 2H), 1.15–1.03(m, 2H), 1.00(d, J=6.6Hz, 3H), 0.97–0.88(m, 13H), 0.54 (q, J=7.9Hz, 6H), 0.50–0.43 (m, 1H), 0.36–0.27 (m, 1H), 0.21 (dt, J=9.6, 4.8Hz, 1H).

[0113] 13 C NMR (151 MHz, CDCl 3 )δ136.69, 126.81, 67.58, 54.48, 51.36, 40.34, 38.94, 37.56, 32.85, 25.88, 21.22, 18.39, 15.91, 15.84, 11.95, 5.14, 3.15, 1.27.-0.01.

[0114] S6: Preparation of intermediate 8:

[0115] Dissolve 12 g of the compound of formula 7 in 240 mL of tetrahydrofuran, add the solution into a three-necked flask, protect with nitrogen, add 28 g of tetrabutylammonium fluoride trihydrate, and heat to 55-60° C. with stirring. The reaction was allowed to proceed for 2 h to 4 h, and the reaction was detected by TLC (developing agent: n-hexane: ethyl acetate = 4:1, and UV / PMA was used for color development (in TLC, ultraviolet light (UV) and / or certain color developers, such as phosphomolybdic acid, usually referred to as PMA, are used to detect and analyze compounds), Rf≈0.7 for the compound of formula 7, and Rf≈0.3 for the compound of formula 8). After the reaction was completed, water was added, and the phases were separated. The aqueous phase was extracted with EA (200 mL*2), washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, and distilled under reduced pressure until no fraction flowed out (-0.09 to -0.06 MPa, 40.0 to 45.0°C), purified by column chromatography, and the product was collected and distilled under reduced pressure until no fraction flowed out (-0.09 to -0.06 MPa, 40.0 to 45.0°C) to obtain a crude oily substance, which was crystallized to obtain 3.0 g of white crystals to obtain the compound of formula 8.

[0116] LCMS (Liquid Chromatography-Mass Spectrometry: Rt = 10.90-11.82 min; m / z 300.23 (M+Na) + .

[0117] 1 H NMR (600MHz, Chloroform-d) δ5.24 (dd, J=4.7, 2.5Hz, 2H), 3.86 (s, 1H), 3.25–3.17 (m, 1H), 1.91–1.82 ( m, 1H), 1.79–1.72 (m, 1H), 1.63–1.56 (m, 2H), 1.51–1.40 (m, 2H), 1.36–1.28 (m, 1H), 1.26–1.20 (m, 3H), 1.13 (q, J=7.2, 6.2Hz, 2H), 1.08–1.01 (m, 1H), 0.98–0.89 (m, 2H), 0.81 (dd, J=6.6, 2.2Hz, 3H), 0.74 (d, J=2.4Hz, 3H), 0.29 (dt, J=22.6, 4.4Hz, 2H), 0.11 (dt, J=9.4, 3.5Hz, 1H), -0.00 (dt, J=9.6, 4.7Hz, 1H).

[0118] 13 C NMR (151 MHz, CDCl 3)δ136.23, 127.04, 67.49, 54.28, 50.83, 40.00, 38.47, 37.48, 31.74, 25.67, 20.66, 18.33, 15.81, 15.60, 11.89, 1.24, -0.00.

[0119] S7: Preparation of intermediate 9 (compound of formula 9):

[0120] 2.1 g of compound 8, 42 mL of dichloromethane and 0.9 g of imidazole were added to a three-necked flask in sequence, stirred evenly under nitrogen protection, cooled to 0°C to 5°C, 1.3 g of tert-butyldimethylsilyl chloride was added, and the reaction was carried out for 2-5 hours. The reaction was detected by TLC (developing solvent: n-hexane: ethyl acetate = 4:1, UV / PMA color development, Rf≈0.7 for compound 8, Rf≈0.3 for compound 9), and after the reaction was completed, it was distilled under reduced pressure (-0.09 to -0.06 MPa, 40.0 to 45.0°C), separated by column chromatography, eluted with PE:EA=10:1, and the product was collected and distilled under reduced pressure until no fraction flowed out (-0.09 to -0.06 MPa, 40.0 to 45.0°C) to obtain 1.8 g of compound 9 as an oil.

[0121] LCMS: Rt=8.03~8.23min; m / z 415.21(M+Na) + .

[0122] 1 H NMR (600MHz, Chloroform-d) δ5.36–5.28 (m, 2H), 4.07 (q, J=2.8Hz, 1H), 3.60 (t, J=6.3Hz, 1H) , 2.04(s, 1H), 2.00–1.95(m, 1H), 1.84–1.77(m, 2H), 1.75–1.63(m, 2H), 1.54–1.48(m, 1H), 1.4 3(d, J=9.9Hz, 3H), 1.36–1.31(m, 2H), 1.21–1.06(m, 2H), 1.00(d, J=6.6Hz, 3H), 0.95(s, 3H), 0.87 (s, 9H), 0.44–0.34 (m, 2H), 0.31–0.25 (m, 1H), 0.21–0.16 (m, 1H), 0.02 (d, J=11.2Hz, 6H).

[0123] 13 C NMR (151 MHz, CDCl 3)δ133.74, 128.02, 66.99, 53.85, 50.28, 39.41, 37.92, 36.87, 31.18, 25.08, 24.52, 23.5 4, 23.25, 20.16, 17.79, 15.88, 15.55, 15.05, 11.33, -0.00, -0.91, -5.99, -6.51, -6.91.

[0124] S8: Preparation of intermediate 10:

[0125] Add 3.0 g of the compound of formula 9 and 3.9 mL of dichloromethane into a 50 mL three-necked flask, stir evenly, add 3.3 g of Dess-Martin reagent, react for 0.5 to 2 h, detect the reaction by TLC (PE:EA=8:1, Rf≈0.3 for the compound of formula 9, Rf≈0.4 for the compound of formula 10, color development with phosphomolybdic acid), after the reaction is completed, filter, distill under reduced pressure (25.0 to 30.0°C, -0.09 to -0.6 MPa), and purify by column chromatography (PE:EA=10:1 elution) to obtain 1.5 g of the compound of formula 10 as a light yellow oil.

[0126] 1 H NMR (600MHz, Chloroform-d) δ5.43–5.28 (m, 2H), 3.58 (t, J=6.3Hz, 1H), 2.49–2.41 (m, 1H), 2.30–2.17 (m, 2H), 2.11 –2.04 (m, 2H), 2.01 (dddt, J=14.4, 7.1, 4.6, 2.2Hz, 1H), 1.90 (dtdd, J=14.0, 12.8, 5.9, 4.6Hz, 1H), 1.74–1.66 (m, 2H ), 1.59 (td, J=13.1, 4.9Hz, 1H), 1.52–1.42 (m, 2H), 1.32–1.27 (m, 1H), 1.05 (d, J=6.7Hz, 3H), 0.87 (s, 10H), 0.64 (s , 3H), 0.43–0.34 (m, 2H), 0.30–0.24 (m, 1H), 0.17 (dtd, J=9.5, 5.2, 3.8Hz, 1H), 0.08 (s, 1H), 0.01 (d, J=13.0Hz, 6H).

[0127] 13C NMR (151MHz, CHLOROFORM-D) δ212.01, 135.20, 131.05, 76.29, 61.96, 56.22, 49.77, 40.94, 39.31, 38.80, 27.54, 25.90, 25.63, 24.04, 20.45, 19.07, 18.25, 17.88, 12.71, 2.46, 1.50, -4.17, -4.53.

[0128] S9: Preparation of intermediate 12:

[0129] 1.8 g of the compound of formula 10 and 5 mL of dry tetrahydrofuran were added to a 500 mL three-necked flask, and the mixture was stirred under argon protection until it was completely dissolved. The mixture was cooled to -80 to -70°C, 2.6 mL of lithium hexamethyldisilazide was added dropwise, and the reaction was carried out for 1-2 hours. 4.6 g of the compound of formula 11 was added dropwise, and the reaction was carried out for 1-2 hours. The reaction was detected by TLC (PE:EA=8:1, Rf≈0.3 for the compound of formula 10, Rf≈0.5 for the compound of formula 11, and phosphomolybdic acid was used for color development). After the reaction was completed, water was added to quench the mixture, and the mixture was extracted with ethyl acetate, washed once with a saturated sodium chloride aqueous solution, dried over anhydrous sodium sulfate, and distilled under reduced pressure until no fraction flowed out (30 to 35°C, -0.09 to -0.08 MPa). The mixture was purified by column chromatography (PE:EA=15:1 elution) to obtain 0.8 g of the compound of formula 12 as a light yellow oil.

[0130] NMR: 1 H NMR (600MHz, Chloroform-d) δ6.22 (d, J=11.2Hz, 1H), 6.00 (d,

[0131] J=11.2Hz, 1H), 5.35 (dd, J=6.4, 5.0Hz, 1H), 5.25 (s, 1H), 4.97 (d, J=2.7Hz, 1H), 4.23–4.17 (m, 2H), 3.74–3.64 (m, 4H), 3.64–3.59 (m, 2H), 3.25– 3.20 (m, 1H), 2.82 (dd, J=12.2, 4.1Hz, 1H), 2.47 (d, J=13.6Hz, 1H), 2.21 (dd, J=12.9, 3.9Hz, 1H), 2.09–2.03(m, 1H), 2.01–1.95(m, 2H), 1.78(td, J=6.5, 3.4Hz, 2H), 1.71–1.62 (m, 3H), 1.55 (d, J=17.4Hz, 2H), 1.43 (td, J=7.7, 4.5Hz, 2H), 1.31 (t, J=9.4Hz, 3H), 1.03 (d, J=6.6Hz, 3H), 0.88 (dd , J=5.3, 2.3Hz, 36H), 0.54 (s, 3H), 0.39 (dddd, J=13.6, 8.6, 5.5, 3.9Hz, 2H), 0.32–0.26 (m, 1H), 0.20 (dt, J=7.8, 2.9Hz, 1H), 0.07–0.01 (m, 24H).

[0132] 13 C NMR (151 MHz, CDCl 3 )δ139.43, 134.75, 133.08, 128.95, 121.70, 116.49, 74.98, 68.02, 66.74 ,58.99,54.88,54.66,44.23,39.02,38.44,32.12,27.36,26.22,24.49,2 4.47, 24.39, 24.34, 21.99, 20.69, 19.07, 16.83, 16.74, 16.70, 16.47, 10.76, 0.91, -0.00, -5.59, -5.98, -6.07, -6.10, -6.17, -6.28, -6.36, -6.78

[0133] S10: Preparation of compound of formula 13:

[0134] 4 g of the compound of formula 12, 100 mL of tetrahydrofuran, and 7 g of tetrabutylammonium fluoride trihydrate were added to a 500 mL three-necked flask, protected by argon, and stirred. After the materials were completely dissolved, the system was heated to 55-60° C. and reacted for 2-4 hours. The reaction was detected by TLC (pure ethyl acetate display plate, Rf≈0.9 for the compound of formula 12, Rf≈0.4 for the compound of formula 13, and color development with phosphomolybdic acid). After the reaction was completed, the mixture was distilled under reduced pressure until no solvent flowed out (30-35° C., -0.09-0.08 MPa), purified by column chromatography (PE:EA=1:5 elution), and crystallized to obtain 1 g of the compound of formula 13.

[0135] LCMS: Rt=8.44~8.59min; m / z509.32(M+Na) + .

[0136] 1 H NMR (600MHz, DMSO-d6) δ6.19 (d, J=11.2Hz, 1H), 5.96 (d, J=11.1Hz, 1H), 5.39–5.28 (m, 3H), 5.00 (d, J = 4.8Hz, 1H), 4.84 (dd, J = 3.1, 1.6Hz, 1H), 4.56 (d, J = 4.6Hz, 1H), 4.43 (d, J=4.2Hz, 1H), 4.37 (t, J=5.2Hz, 1H), 4.08–3.98 (m, 2H), 3.64 (dt, J=9.6, 6 .4Hz, 1H), 3.55 (dt, J=9.6, 6.4Hz, 1H), 3.49 (q, J=6.0Hz, 2H), 3.35 (dd, J=8.3, 3.6H z, 1H), 3.10 (dd, J=7.9, 2.7Hz, 1H), 2.80 (dd, J=12.9, 4.1Hz, 1H), 2.33 (dd, J=13.9 , 6.1Hz, 1H), 2.25–2.17 (m, 1H), 2.07–1.86 (m, 3H), 1.65 (td, J=11.4, 10.2, 4.9Hz, 5 H), 1.47–1.20 (m, 6H), 1.00 (d, J=6.5Hz, 3H), 0.83–0.75 (m, 1H), 0.52 (s, 3H), 0.38 –0.28 (m, 2H), 0.22 (ddt, J=9.4, 4.7, 2.2Hz, 1H), 0.13 (ddd, J=9.4, 6.2, 3.7Hz, 1H).

[0137] 13C NMR (151MHz, DMSO) δ144.58, 138.31, 133.13, 133.01, 128.68, 120.74, 115.67, 110.29, 81.95, 72.11, 69.26, 64.94, 64.08 , 56.28, 53.72, 53.69, 43.29, 38.82, 38.11, 30.94, 26.43, 25.26, 21.20, 19.89, 18.52, 15.67, 10.02, 0.67, -0.50, -1.87.

[0138] Example 2

[0139] A method for preparing a vitamin D derivative compound, such as Figure 2 As shown, the following steps are included:

[0140] Step 1, using compound 1 as a starting material, reacting in an organic solvent reaction system, and protecting the hydroxyl group with a hydroxyl protecting agent under the action of a base to obtain compound 2.

[0141] The added hydroxyl protecting agent is tert-butyldimethylsilyl and tert-butyldiphenylsilyl, the organic solvent is dichloromethane, and the molar ratio of compound 1 to the hydroxyl protecting agent is 1:2.

[0142] Step 2: Compound 2 is reacted with 4-methylbenzenesulfonate pyridine in an organic solvent reaction system at room temperature to selectively remove the protecting group to obtain compound 3.

[0143] Wherein, the organic solvent is dichloromethane; and the molar ratio of the compound 2 to 4-methylbenzenesulfonate pyridine is 1:2.

[0144] Step 3, adding an oxidant to the compound 3 in an organic solvent reaction system to obtain compound 4.

[0145] Wherein, the oxidant is Dess-Martin periodinane, the organic solvent is dichloromethane, the molar ratio of compound 3 to the oxidant is 1:1.5, and the reaction temperature of step 3 is -10°C.

[0146] Step 4, compound 4 and compound 5 undergo Wittig reaction in an organic solvent to obtain compound 6.

[0147] The organic solvent is tetrahydrofuran, the molar ratio of compound 4 to compound 5 is 1:1.5, and when compound 4 and compound 5 react, the reaction temperature is 25° C. and the reaction time is 12 h to obtain compound 6.

[0148] Step 5, compound 6 is subjected to chiral reduction reaction in an organic solvent system to obtain compound 7.

[0149] Wherein, the organic solvent is tetrahydrofuran; in the chiral reduction, the compound 6 reacts with the chiral ligand under the reduction of the reducing agent to obtain compound 7; the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:0.6:1.0. In the chiral reduction reaction, the chiral catalyst used is (R)-2-methyl-CBS-oxazaborolidine. In this step, the reaction temperature is -50°C and the reaction time is 2h.

[0150] Step 6, removing the protecting group of compound 7 in an organic solvent reaction system to obtain compound 8.

[0151] Wherein, the organic solvent is dichloromethane;

[0152] Step 7, the hydroxyl group of the compound 8 is selectively protected in an organic solvent to obtain compound 9.

[0153] Wherein, the organic solvent is dichloromethane;

[0154] Step 8: Add an oxidant to the compound of formula 9 in an organic solvent to react to obtain a compound of formula 10.

[0155] Wherein, the oxidant is Dess-Martin periodinane; the organic solvent is dichloromethane; and the molar ratio of the compound 9 to the oxidant is 1:1.5.

[0156] Step 9: The compound of formula 10 and the compound of formula 11 are subjected to Horner-Wadsworth-Emmons reaction in an organic solvent at a reaction temperature of -80°C to obtain a compound of formula 12.

[0157] Wherein, the organic solvent is tetrahydrofuran; the molar ratio of the compound of formula 10 to the compound of formula 11 is 1:1.2.

[0158] Step 10, adding an acid to the compound of formula 12 in an organic solvent to remove the protecting group to obtain a compound of formula 13, i.e., a vitamin D derivative compound.

[0159] Wherein, the acid is DL-camphorsulfonic acid, the organic solvent is tetrahydrofuran, and the molar ratio of the compound of formula 12 to the acid is 1:2.

[0160] Example 3

[0161] A method for preparing a vitamin D derivative compound comprises the following steps:

[0162] Step 1, using compound 1 as a starting material, reacting in an organic solvent reaction system, and protecting the hydroxyl group with a hydroxyl protecting agent under the action of a base to obtain compound 2.

[0163] The added hydroxyl protecting agent is triisopropylsilyl, the organic solvent is chloroform, and the molar ratio of compound 1 to the hydroxyl protecting agent is 1:4.

[0164] Step 2: Compound 2 is reacted with 4-methylbenzenesulfonate pyridine in an organic solvent reaction system at room temperature to selectively remove the protecting group to obtain compound 3.

[0165] The organic solvent is tetrahydrofuran, and the molar ratio of compound 2 to 4-methylbenzenesulfonate pyridine is 1:4.

[0166] Step 3, adding an oxidant to the compound 3 in an organic solvent reaction system to obtain compound 4.

[0167] The oxidant is pyridinium chlorochromate, the organic solvent is tetrahydrofuran, the molar ratio of compound 3 to the oxidant is 1:4, and the reaction temperature is 10°C.

[0168] Step 4, compound 4 and compound 5 undergo Wittig reaction in an organic solvent to obtain compound 6.

[0169] The organic solvent is 2-methyltetrahydrofuran, the molar ratio of compound 4 to compound 5 is 1:4.5, the reaction temperature is 80° C., and the reaction time is 4 h.

[0170] Step 5, compound 6 is subjected to chiral reduction reaction in an organic solvent system to obtain compound 7.

[0171] The organic solvent is 2-methyltetrahydrofuran; in the chiral reduction, the compound 6 reacts with the chiral ligand under the reduction of the reducing agent to obtain the compound 7; the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:1.5:3.5. In the chiral reduction reaction, the chiral catalyst used is (R)-2-isopropyl-CBS-oxazaborolidine, and in this step, the reaction temperature is -10°C and the reaction time is 2h.

[0172] Step 6, removing the protecting group of compound 7 in an organic solvent reaction system to obtain compound 8.

[0173] Wherein, the organic solvent is tetrahydrofuran;

[0174] Step 7, the hydroxyl group of the compound 8 is selectively protected in an organic solvent to obtain compound 9.

[0175] Wherein, the organic solvent is chloroform;

[0176] Step 8: Add an oxidant to the compound of formula 9 in an organic solvent to react to obtain a compound of formula 10.

[0177] Wherein, the oxidant is pyridinium chlorochromate; the organic solvent is tetrahydrofuran; and the molar ratio of the compound 9 to the oxidant is 1:4.0.

[0178] Step 9, the compound of formula 10 and the compound of formula 11 are subjected to Horner-Wadsworth-Emmons reaction in an organic solvent at a reaction temperature of -30°C to obtain a compound of formula 12, wherein the organic solvent is 2-methyltetrahydrofuran; the molar ratio of the compound of formula 10 to the compound of formula 11 is 1:3.5.

[0179] Step 10, adding an acid to the compound of formula 12 in an organic solvent to remove the protecting group to obtain a compound of formula 13, i.e., a vitamin D derivative compound.

[0180] Wherein, the acid is L-camphorsulfonic acid, the organic solvent is 2-methyltetrahydrofuran, and the molar ratio of the compound of formula 12 to the acid is 1:5.5.

[0181] Example 4

[0182] A method for preparing a vitamin D derivative compound comprises the following steps:

[0183] Step 1, using compound 1 as a starting material, reacting in an organic solvent reaction system, and protecting the hydroxyl group with a hydroxyl protecting agent under the action of a base to obtain compound 2.

[0184] The added hydroxyl protecting agent is triethylsilyl, the organic solvent is 1,2-dichloroethane, and the molar ratio of compound 1 to the hydroxyl protecting agent is 1:3.

[0185] Step 2: Compound 2 is reacted with 4-methylbenzenesulfonate pyridine in an organic solvent reaction system at room temperature to selectively remove the protecting group to obtain compound 3.

[0186] The organic solvent is 2-methyltetrahydrofuran, and the molar ratio of compound 2 to 4-methylbenzenesulfonate pyridine is 1:3.

[0187] Step 3, adding an oxidant to the compound 3 in an organic solvent reaction system to obtain compound 4.

[0188] Wherein, the oxidant is pyridinium dichromate, the organic solvent is 2-methyltetrahydrofuran, the molar ratio of compound 3 to the oxidant is 1:3, and the reaction temperature is 5°C.

[0189] Step 4, compound 4 and compound 5 undergo Wittig reaction in an organic solvent to obtain compound 6.

[0190] The organic solvent is N,N-dimethylformamide, the molar ratio of compound 4 to compound 5 is 1:2, the reaction temperature is 50° C., and the reaction time is 10 h.

[0191] Step 5, the compound 6 is subjected to chiral reduction reaction in an organic solvent system to obtain a stereoisomer of the compound 7.

[0192] The organic solvent is methanol and ethanol; in the chiral reduction, the compound 6 reacts with the chiral ligand under the reduction of the reducing agent to obtain the stereoisomer of the compound 7; the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:1:2. In the chiral reduction reaction, the chiral catalyst used is (S)-2-methyl-CBS-oxazaborolidine solution, the reaction temperature is -5°C, and the reaction time is 4h.

[0193] Step 6, removing the protecting group of the stereoisomer of compound 7 in an organic solvent reaction system to obtain the stereoisomer of compound 8.

[0194] Wherein, the organic solvent is 2-methyltetrahydrofuran;

[0195] Step 7, the stereoisomer of compound 8 is subjected to selective protection of the hydroxyl group in an organic solvent to obtain the stereoisomer of compound 9.

[0196] Wherein, the organic solvent is 1,2-dichloroethane;

[0197] Step 8: Add an oxidant to the stereoisomer of the compound of formula 9 in an organic solvent to react to obtain the stereoisomer of the compound of formula 10.

[0198] Wherein, the oxidant is pyridinium dichromate; the organic solvent is 2-methyltetrahydrofuran, and the molar ratio of the stereoisomer of compound 9 to the oxidant is 1:3.

[0199] Step 9, the stereoisomer of the compound of formula 10 and the compound of formula 11 are subjected to a Horner-Wadsworth-Emmons reaction in an organic solvent at a reaction temperature of -50°C to obtain a stereoisomer of the compound of formula 12, wherein the organic solvent is a mixture of tetrahydrofuran and 2-methyltetrahydrofuran; the molar ratio of the stereoisomer of the compound of formula 10 to the compound of formula 11 is 1:2.

[0200] Step 10, adding an acid to the stereoisomer of the compound of formula 12 in an organic solvent to remove the protecting group, thereby obtaining the stereoisomer of the compound of formula 13, i.e., a vitamin D derivative compound.

[0201] Wherein, the acid is dextrorotatory camphorsulfonic acid, the organic solvent is a mixture of tetrahydrofuran and 2-methyltetrahydrofuran; and the molar ratio of the stereoisomer of the compound of formula 12 to the acid is 1:3.

[0202] Example 5

[0203] In order to verify the biological activity of the vitamin D derivative compounds obtained in the present invention, the following tests were carried out using the compound of formula (II):

[0204] Purpose

[0205] The activation activity of the compounds of the present invention was detected in the GAL4-VDR-Luc / HEK293 stably transfected cell line.

[0206] Experimental instruments

[0207] Microplate reader: Envision (Perkin Elmer)

[0208] Automated pipetting workstation: Bravo (Agilent)

[0209] Micropipette: Echo (LABCYTE)

[0210] Cell counter: Counter star (Count star-IC-1000)

[0211] CO 2 Cell culture incubator: MCO-15AC (Thermo Fisher)

[0212] Pipette: RAININ Multichannel

[0213] Centrifuge: Thermo Centrifuge ST 40R

[0214] Refrigerator: Haier ultra-low temperature refrigerator, Haier 4-degree refrigerator, Haier -20-degree refrigerator

[0215] Test methods

[0216] The activation activity of the compounds was detected in the GAL4-VDR-Luc / HEK293 stable cell line, and the activation efficacy of the compounds was evaluated by detecting the expression level of the reporter gene using Bright-glo detection reagent (Promega: E2620).

[0217] Specific operations

[0218] 1. Cell Plating

[0219] 1) Preheat PBS, 0.25% trypsin and complete culture medium in a 37°C water bath.

[0220] 2) Observe the cells under a microscope to assess cell confluence and confirm the absence of bacterial and fungal contamination.

[0221] 3) Remove the supernatant medium and wash the cells once with 5 mL PBS. Add 2 mL 0.06% trypsin / EDTA reagent to a 10 cm culture dish and place the dish in an incubator until the cells are detached. Add 8 mL complete cell culture medium to terminate digestion, aspirate and transfer to a 15 mL centrifuge tube, and centrifuge at 1000 rpm / min for 5 minutes.

[0222] 4) After centrifugation, discard the supernatant, resuspend the cells with 5 mL of fresh cell culture medium, take 20 uL of cell suspension, add 20 ul of trypan blue dye, mix well, and use Cell Counter Star to record the number of live cells and cell viability.

[0223] 5) Use fresh complete cell culture medium to adjust the volume of cell suspension to the desired cell density (0.4×10^6 cells / ml).

[0224] 6) According to the following experimental cell plate arrangement, add 25uL of cell suspension to each well of a 384-well plate (Corning 3765) and centrifuge at 1000rpm / min for 1 minute.

[0225] 7) Place the cell plate in a 37°C, 5% CO2 constant temperature incubator and incubate for 16 hours.

[0226] 2. Preparation of compound solution:

[0227] 1) Dissolve compound Y1 powder in DMSO to a stock concentration of 10 mM.

[0228] 2) Compound Y1 was diluted from the stock concentration of 10 mM to the working concentration of 1000 uM (1000X, 100% DMSO) with DMSO, and compound Y1 was diluted three-fold from the working concentration into ten gradients (1000X, 100% DMSO) with DMSO.

[0229] 3) Use Echo to transfer 180 nL of the diluted compound Y1 to a 384-well plate (Greiner 781201), then add 29.8 uL of cell culture medium (6X, 0.6% DMSO) and mix well.

[0230] 4) Transfer 5uL of 6x compound Y1 prepared in the above culture medium to a 384-well plate with cells (1X, 0.1% DMSO), and centrifuge at 1000 rpm / min for 1 minute.

[0231] 5) Place the well plate in a 37°C, 5% CO2 cell culture incubator and incubate for 16 hours.

[0232] 3. Detection

[0233] 1) Equilibrate the Bright-glo detection reagent to room temperature.

[0234] 2) Take the cell plate out of the constant temperature incubator, add 15uL of detection reagent to each well, and centrifuge at 1000rpm for 1 minute.

[0235] 3) Use Envision to read the chemiluminescent signal value.

[0236] Experimental data processing method

[0237] Activation rate % = 100*(signal value - negative control signal value) / (positive control signal value - negative control signal value)

[0238] Experimental conclusion

[0239] 1) The entire plate meets the QC standard (Z'>0.5). Table 1 shows the results of the life activity test of the compound of formula (II) of the present invention. It can be seen from Table 1 that the vitamin D derivatives prepared by the technology of the present invention have good biological activity. In the table, the Z factor is a statistical data quality standard for biological assays. During high-throughput screening of compounds, each compound in the compound library is evaluated only once during the preliminary screening. Therefore, high accuracy and sensitivity of the assay are crucial for identifying active compounds. For high-quality and stable assays, the Z value is generally between 0.5 and 1. In this test, the Z factor value was 0.82, so the assay met the QC (quality control) standard.

[0240] Table 1

[0241]

[0242] 2) Table 2 shows the results of the life activity test of the compound of formula (II) of the present invention. It can be seen from Table 2 that the maximum concentration activation rate is 100%, the minimum concentration activation rate is about 0, the slope of the compound dosage curve is 0.67, and the relative EC50 is 21.15nM. It can be seen from Table 2 that the EC50 of the compound of formula (II) of the present invention is 21.15nM. EC50 (half effective concentration) refers to the concentration of a substance that causes 50% of the maximum effect (such as activation rate, inhibition rate, etc.) in an in vitro experiment. It is an important indicator for evaluating the activity of a drug or compound. The smaller the EC50 value, the stronger the activity of the compound. The EC50 of compound (II) in the present invention is 21.15nM, indicating that in an in vitro experiment, the compound (II) can cause a 50% maximum activation effect at a concentration of 21.15nM.

[0243] Table 2

[0244] Compound ID Top Bottom Slope Relative EC50(nM) Compound of formula (II) 100.0 -0.4 0.67 21.15

[0245] Wherein, the compound of formula (II) is:

[0246]

[0247] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

[0248] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A vitamin D derivative compound, characterized in that: Including compounds represented by general formula (I), or stereoisomers of general formula (I): Wherein n is 1 to 5.

2. A method for preparing a vitamin D derivative compound according to claim 1, characterized in that: The following steps are involved: Step 1, reacting compound 1 with a hydroxyl protecting agent under the action of a base to obtain compound 2; The compound 1 is Compound 2 is Step 2, reacting the compound 2 with 4-methylbenzenesulfonate pyridine at room temperature to obtain compound 3; The compound 3 is Step 3, reacting the compound 3 with an oxidant to obtain a compound 4; The compound 4 is Step 4, subjecting the compound 4 to a Wittig reaction with the compound 5 to obtain the compound 6; The compound 6 is Step 5, reacting the compound 6 with a chiral ligand and a reducing agent to obtain a compound 7 or a stereoisomer thereof; The compound 7 is Step 6, removing the protecting group on the compound 7 or its stereoisomer to obtain the compound 8 or its stereoisomer; The compound 8 is Step 7, reacting the compound 8 or its stereoisomer with a hydroxyl protecting agent to obtain a compound 9 or its stereoisomer; The compound 9 is Step 8, the compound 9 or its stereoisomer reacts with an oxidant to obtain a compound of formula 10 or its stereoisomer; The compound 10 is Step 9, subjecting the compound 10 or its stereoisomer to a Horner-Wadsworth-Emmons reaction with the compound 11 in an organic solvent to obtain a compound 12 or its stereoisomer; The compound 12 is Step 10, reacting the compound 12 or its stereoisomer with an acid to remove the protecting group, thereby obtaining the compound represented by the general formula (I) or its stereoisomer.

3. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: The hydroxyl protecting agent used in step 1 and step 7 is any one of tert-butyldimethylsilyl, tert-butyldiphenylsilyl, triisopropylsilyl, diphenylmethylsilyl and triethylsilyl.

4. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In step 1, the molar ratio of the compound 1 to the hydroxyl protecting agent is 1:(2-4).

5. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In step 2, the molar ratio of the compound 2 to 4-methylbenzenesulfonate pyridine is 1:(2-4).

6. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In step 3, the molar ratio of the compound 3 to the oxidant is 1:(1.5-4).

7. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In step 4, the molar ratio of compound 4 to compound 5 is 1:(1.5-4.5), the reaction temperature is 25-80° C., and the reaction time is 4-12 h.

8. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In step 5, the molar ratio of the compound 6 to the chiral ligand and the reducing agent is 1:(0.6-1.5):(1.0-3.5).

9. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: The oxidizing agent used in step 3 and step 8 is any one of Dess-Martin periodinane, pyridinium chlorochromate and pyridinium dichromate.

10. The method for preparing a vitamin D derivative compound according to claim 2, characterized in that: In the step 10, the acid is any one or more of DL-camphorsulfonic acid, L-camphorsulfonic acid, and D-camphorsulfonic acid; in the step 10, the molar ratio of the compound 12 to the acid is 1:(2-5.5).